Drug Profile
GLWL 01
Alternative Names: GLWL-01Latest Information Update: 05 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer GLWL Research
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Ghrelin O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prader-Willi syndrome; Type 2 diabetes mellitus
Most Recent Events
- 05 Oct 2021 No development reported - Phase-II for Prader-Willi syndrome in USA, Canada (PO) (GLWL Research website, October 2021)
- 12 Jun 2019 GLWL Research completes a phase II trial in Prader-Willi syndrome in Canada and USA (NCT03274856)
- 09 Apr 2019 National Institute on Alcohol Abuse and Alcoholism plans a phase I/II trial in Alcoholism in USA in April 2019 (NCT03896516)